These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30530501)

  • 1. Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
    Barazas M; Gasparini A; Huang Y; Küçükosmanoğlu A; Annunziato S; Bouwman P; Sol W; Kersbergen A; Proost N; de Korte-Grimmerink R; van de Ven M; Jonkers J; Borst GR; Rottenberg S
    Cancer Res; 2019 Feb; 79(3):452-460. PubMed ID: 30530501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
    Dev H; Chiang TW; Lescale C; de Krijger I; Martin AG; Pilger D; Coates J; Sczaniecka-Clift M; Wei W; Ostermaier M; Herzog M; Lam J; Shea A; Demir M; Wu Q; Yang F; Fu B; Lai Z; Balmus G; Belotserkovskaya R; Serra V; O'Connor MJ; Bruna A; Beli P; Pellegrini L; Caldas C; Deriano L; Jacobs JJL; Galanty Y; Jackson SP
    Nat Cell Biol; 2018 Aug; 20(8):954-965. PubMed ID: 30022119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
    Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity.
    Gupta R; Somyajit K; Narita T; Maskey E; Stanlie A; Kremer M; Typas D; Lammers M; Mailand N; Nussenzweig A; Lukas J; Choudhary C
    Cell; 2018 May; 173(4):972-988.e23. PubMed ID: 29656893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
    Jaspers JE; Kersbergen A; Boon U; Sol W; van Deemter L; Zander SA; Drost R; Wientjens E; Ji J; Aly A; Doroshow JH; Cranston A; Martin NM; Lau A; O'Connor MJ; Ganesan S; Borst P; Jonkers J; Rottenberg S
    Cancer Discov; 2013 Jan; 3(1):68-81. PubMed ID: 23103855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. REV7 counteracts DNA double-strand break resection and affects PARP inhibition.
    Xu G; Chapman JR; Brandsma I; Yuan J; Mistrik M; Bouwman P; Bartkova J; Gogola E; Warmerdam D; Barazas M; Jaspers JE; Watanabe K; Pieterse M; Kersbergen A; Sol W; Celie PHN; Schouten PC; van den Broek B; Salman A; Nieuwland M; de Rink I; de Ronde J; Jalink K; Boulton SJ; Chen J; van Gent DC; Bartek J; Jonkers J; Borst P; Rottenberg S
    Nature; 2015 May; 521(7553):541-544. PubMed ID: 25799992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.
    Nacson J; Krais JJ; Bernhardy AJ; Clausen E; Feng W; Wang Y; Nicolas E; Cai KQ; Tricarico R; Hua X; DiMarcantonio D; Martinez E; Zong D; Handorf EA; Bellacosa A; Testa JR; Nussenzweig A; Gupta GP; Sykes SM; Johnson N
    Cell Rep; 2018 Sep; 24(13):3513-3527.e7. PubMed ID: 30257212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
    Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
    Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
    Paes Dias M; Tripathi V; van der Heijden I; Cong K; Manolika EM; Bhin J; Gogola E; Galanos P; Annunziato S; Lieftink C; Andújar-Sánchez M; Chakrabarty S; Smith GCM; van de Ven M; Beijersbergen RL; Bartkova J; Rottenberg S; Cantor S; Bartek J; Ray Chaudhuri A; Jonkers J
    Mol Cell; 2021 Nov; 81(22):4692-4708.e9. PubMed ID: 34555355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 53BP1 Enforces Distinct Pre- and Post-resection Blocks on Homologous Recombination.
    Callen E; Zong D; Wu W; Wong N; Stanlie A; Ishikawa M; Pavani R; Dumitrache LC; Byrum AK; Mendez-Dorantes C; Martinez P; Canela A; Maman Y; Day A; Kruhlak MJ; Blasco MA; Stark JM; Mosammaparast N; McKinnon PJ; Nussenzweig A
    Mol Cell; 2020 Jan; 77(1):26-38.e7. PubMed ID: 31653568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 53BP1-shieldin-dependent DSB processing in BRCA1-deficient cells requires CST-Polα-primase fill-in synthesis.
    Mirman Z; Sasi NK; King A; Chapman JR; de Lange T
    Nat Cell Biol; 2022 Jan; 24(1):51-61. PubMed ID: 35027730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone chaperone ASF1 acts with RIF1 to promote DNA end joining in BRCA1-deficient cells.
    Tang M; Chen Z; Wang C; Feng X; Lee N; Huang M; Zhang H; Li S; Xiong Y; Chen J
    J Biol Chem; 2022 Jun; 298(6):101979. PubMed ID: 35472331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRIP13 regulates DNA repair pathway choice through REV7 conformational change.
    Clairmont CS; Sarangi P; Ponnienselvan K; Galli LD; Csete I; Moreau L; Adelmant G; Chowdhury D; Marto JA; D'Andrea AD
    Nat Cell Biol; 2020 Jan; 22(1):87-96. PubMed ID: 31915374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 53BP1-RIF1-shieldin counteracts DSB resection through CST- and Polα-dependent fill-in.
    Mirman Z; Lottersberger F; Takai H; Kibe T; Gong Y; Takai K; Bianchi A; Zimmermann M; Durocher D; de Lange T
    Nature; 2018 Aug; 560(7716):112-116. PubMed ID: 30022158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
    Yang ZM; Liao XM; Chen Y; Shen YY; Yang XY; Su Y; Sun YM; Gao YL; Ding J; Zhang A; He JX; Miao ZH
    Acta Pharmacol Sin; 2017 Jul; 38(7):1038-1047. PubMed ID: 28414200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FAM35A associates with REV7 and modulates DNA damage responses of normal and BRCA1-defective cells.
    Tomida J; Takata KI; Bhetawal S; Person MD; Chao HP; Tang DG; Wood RD
    EMBO J; 2018 Jun; 37(12):. PubMed ID: 29789392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The p53-binding protein 1-Tudor-interacting repair regulator complex participates in the DNA damage response.
    Zhang A; Peng B; Huang P; Chen J; Gong Z
    J Biol Chem; 2017 Apr; 292(16):6461-6467. PubMed ID: 28213517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
    Aly A; Ganesan S
    J Mol Cell Biol; 2011 Feb; 3(1):66-74. PubMed ID: 21278454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
    Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
    Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
    [No Abstract]   [Full Text] [Related]  

  • 20. CHAMP1-POGZ counteracts the inhibitory effect of 53BP1 on homologous recombination and affects PARP inhibitor resistance.
    Fujita H; Ikeda M; Ui A; Ouchi Y; Mikami Y; Kanno SI; Yasui A; Tanaka K
    Oncogene; 2022 May; 41(19):2706-2718. PubMed ID: 35393543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.